• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

    3/6/23 7:54:11 AM ET
    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Secoo Holding Limited (NASDAQ:SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.
    • Entera Bio Ltd. (NASDAQ:ENTX) rose 43.1% to $1.46 in pre-market trading after dropping 5% on Friday. Entera Bio recently announced the FDA's acceptance of a Type D meeting review to affirm design of the pivotal, Phase 3 protocol for EB613 PTH mini tablets, as the first oral osteoanabolic treatment of post-menopausal osteoporosis.
    • BuzzFeed, Inc. (NASDAQ:BZFD) rose 20.7% to $1.87 in pre-market trading. BuzzFeed is expected to release its Q4 financial results on Monday, March 13, 2023, after the closing bell.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 12.5% to $2.80 in pre-market trading after declining around 3% on Friday.
    • Sono Group N.V. (NASDAQ:SEV) rose 12.5% to $0.8301 in pre-market trading after gaining over 10% on Friday. Sono Group recently announced it will focus exclusively on its solar tech company and has terminated the Sion program.
    • Troika Media Group, Inc. (NASDAQ:TRKA) rose 10.6% to $0.57 in pre-market trading after dropping over 4% on Friday.
    • Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 8.6% to $18.19 in pre-market trading after surging around 65% on Friday. Kala Pharmaceuticals recently said Q4 adjusted EPS results were higher year over year.
    • EUDA Health Holdings Limited (NASDAQ:EUDA) shares rose 8.2% to $1.45 in pre-market trading after jumping more than 20% on Friday
    • Seer, Inc. (NASDAQ:SEER) shares rose 6.8% to $5.82 in pre-market trading after surging over 29% on Friday. Seer recently reported better-than-expected Q4 EPS and sales results.
    • Hertz Global Holdings, Inc. (NYSE:HTZ) shares rose 4.7% to $19.65 in pre-market trading. Hertz Global will replace Pebblebrook Hotel Trust in the S&P MidCap 400 effective Monday, March 20.

    Losers

    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) fell 36% to $0.08 in pre-market after gaining 10% on Friday.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) fell 30.7% to $4.38 in pre-market trading after the company reported the full results from the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial, which were presented at the American College of Cardiology’s Annual Scientific Session & Expo together with the World Congress of Cardiology and simultaneously published in the New England Journal of Medicine..
    • Alzamend Neuro, Inc. (NASDAQ:ALZN) shares dropped 28.6% to $0.40 in pre-market trading after gaining around 3% on Friday.
    • Assure Holdings Corp. (NASDAQ:IONM) fell 24.5% to $3.50 in pre-market trading. Assure shares dropped over 22% on Friday after the company announced a 1-for-20 reverse stock split..
    • Sesen Bio, Inc. (NASDAQ:SESN) fell 15.8% to $0.5190 in pre-market trading. Sesen Bio Stockholders recently approved merger with Carisma Therapeutics.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) shares fell 11.8% to $0.3810 in pre-market trading after gaining 11% on Friday. Vivos Therapeutics recently acquired product rights and patents from Advanced Facialdontics, LLC.
    • Performance Shipping Inc. (NASDAQ:PSHG) shares fell 11.7% to $0.98 in pre-market trading. Performance Shipping recently reported pricing of $12.5 million registered direct offering.
    • ObsEva SA (NASDAQ:OBSV) fell 8.7% to $0.21 in pre-market trading. ObsEva shares jumped 117% on Friday following the purchase of 4 million shares by a company director.
    • Curis, Inc. (NASDAQ:CRIS) fell 8.6% to $0.6301 in pre-market trading. Curis is expected to release its Q4 financial results on Thursday, March 9, 2023.
    • Acutus Medical, Inc. (NASDAQ:AFIB) fell 8.3% to $1.10 in pre-market trading after dropping 11% on Friday. Acutus Medical recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4).

    Now Read This: Investor Optimism Improves After Dow Snaps 4-Week Losing Streak

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $ALZN
    $BCAN
    $BZFD

    CompanyDatePrice TargetRatingAnalyst
    Aptera Motors Corp.
    $SEV
    3/9/2026$10.00Buy
    Alliance Global Partners
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    BuzzFeed Inc.
    $BZFD
    11/21/2025$1.00Buy → Hold
    Craig Hallum
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    KALA BIO Inc.
    $KALA
    7/11/2025$12.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by BuzzFeed Inc.

    4 - BuzzFeed, Inc. (0001828972) (Issuer)

    3/11/26 5:39:43 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    CFO Omer Matthew converted options into 1,667 shares and covered exercise/tax liability with 687 shares, increasing direct ownership by 0.29% to 335,545 units (SEC Form 4)

    4 - BuzzFeed, Inc. (0001828972) (Issuer)

    3/11/26 5:39:36 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Director Germano Geno J bought $26,000 worth of Ordinary Shares (20,000 units at $1.30), increasing direct ownership by 100% to 40,000 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    3/11/26 8:30:10 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Aptera Motors Corp. with a new price target

    Alliance Global Partners initiated coverage of Aptera Motors Corp. with a rating of Buy and set a new price target of $10.00

    3/9/26 9:28:24 AM ET
    $SEV
    Auto Manufacturing
    Industrials

    Piper Sandler initiated coverage on Esperion Therapeutics with a new price target

    Piper Sandler initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/25/25 8:41:48 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BuzzFeed downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded BuzzFeed from Buy to Hold and set a new price target of $1.00

    11/21/25 7:50:53 AM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inside BuzzFeed's Secret Lab: Three Apps, a New Company, and a Bet on the Future of the Internet

    For the past year, a small team has been quietly developing a new kind of company. Today at SXSW, Branch Office came out of stealth to preview the first two of many apps.  Download images & logos here BuzzFeed, Inc. (NASDAQ:BZFD) today unveiled Branch Office, a new spinoff company that has been secretly developing a slate of apps designed to reinvent how people connect on the internet. The first two are launching now. More are coming this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260313571948/en/BRANCH OFFICE Branch Office operates independently, with its own founders, its own mandate, and a product philosophy bui

    3/13/26 6:01:00 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

    LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio

    3/12/26 4:27:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BuzzFeed, Inc. Reports Q4 and Full Year 2025 Results

    BuzzFeed, Inc.'s ("BuzzFeed" or the "Company") (NASDAQ:BZFD) fourth quarter and full year (ended December 31, 2025) financial results were in line with its outlook shared in November. In 2025, BuzzFeed grew programmatic advertising by 7% year over year, expanded its studio business with three feature films, and advanced product innovation in key areas. "We believe there is a gap between the value of our individual assets and our market capitalization that suggests significant unrecognized upside," said Jonah Peretti, BuzzFeed Founder & CEO. "In 2026, our focus is demonstrating the value of our brands, Studio IP, and new AI apps to the market, and we're actively exploring strategic options

    3/12/26 4:15:00 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Germano Geno J bought $26,000 worth of Ordinary Shares (20,000 units at $1.30), increasing direct ownership by 100% to 40,000 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    3/11/26 8:30:10 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ellis Sean bought $12,300 worth of Ordinary Shares (10,000 units at $1.23), increasing direct ownership by 6% to 188,098 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    3/9/26 8:30:21 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Rubin Steven D bought $7,450 worth of Ordinary Shares (5,000 units at $1.49), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    2/17/26 8:30:51 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    SEC Filings

    View All

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/12/26 5:40:34 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BuzzFeed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BuzzFeed, Inc. (0001828972) (Filer)

    3/12/26 4:17:40 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Aptera Motors Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aptera Motors Corp (0001786471) (Filer)

    3/12/26 8:19:24 AM ET
    $SEV
    Auto Manufacturing
    Industrials

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Financials

    Live finance-specific insights

    View All

    Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

    LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio

    3/12/26 4:27:00 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BuzzFeed, Inc. Reports Q4 and Full Year 2025 Results

    BuzzFeed, Inc.'s ("BuzzFeed" or the "Company") (NASDAQ:BZFD) fourth quarter and full year (ended December 31, 2025) financial results were in line with its outlook shared in November. In 2025, BuzzFeed grew programmatic advertising by 7% year over year, expanded its studio business with three feature films, and advanced product innovation in key areas. "We believe there is a gap between the value of our individual assets and our market capitalization that suggests significant unrecognized upside," said Jonah Peretti, BuzzFeed Founder & CEO. "In 2026, our focus is demonstrating the value of our brands, Studio IP, and new AI apps to the market, and we're actively exploring strategic options

    3/12/26 4:15:00 PM ET
    $BZFD
    Telecommunications Equipment
    Consumer Discretionary

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Entera Bio Ltd.

    SC 13G/A - Entera Bio Ltd. (0001638097) (Subject)

    11/20/24 1:48:55 PM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $ALZN
    $BCAN
    $BZFD
    Leadership Updates

    Live Leadership Updates

    View All

    Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

    TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman. The appointment follows a period of accelerating progress across Entera's pipeline as the Company plans to advance two oral PTH peptide programs into clinical testing within 2026, a Phase 3 registrational study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism. "

    2/9/26 8:50:09 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aptera Motors Appoints Automotive Industry Veteran Tony Kirton as Chairman of the Board of Directors

    CARLSBAD, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aptera Motors Corp. (NASDAQ:SEV), a solar mobility company advancing ultra-efficient transportation, today announced that Tony Kirton has been appointed Chairman of the Board of Directors. Kirton brings more than four decades of global automotive leadership experience, having held senior executive and board roles across leading automotive brands including Volkswagen, Audi, and BMW. His appointment follows his service as an independent board director and supports Aptera's focus on disciplined governance and long-term value creation as the company prepares for production. "Over my career, I've seen many technologies promise transformation

    1/8/26 4:49:26 PM ET
    $SEV
    Auto Manufacturing
    Industrials

    Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

    – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion.    "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

    11/4/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care